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modeling based corrections might be necessary for 
which the (re)-building of the study model is required.
Univariate sensitivity analysis seems appropriate for 
identiﬁcation of the most important adjustments. If not
all relevant study parameters can be substituted with
country speciﬁc ones, multivariate or probabilistic sensi-
tivity analysis appears to be a promising way to quantify
the uncertainty associated with a transfer. If study results
cannot be transferred, the transfer of study models or
designs should be investigated as this can save a sub-
stantial amount of time when conducting a new study.
CONCLUSIONS: The transferability decision chart is a
transparent and user-friendly tool for evaluating and
improving the transferability of economic evaluation
results. For the assessment of transferability, a detailed
method description in the original study is necessary. In
addition, the relevant data should be presented in a non-
aggregated manner for enabling modeling adjustment.
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OBJECTIVES: In making decisions about which health
care interventions to reimburse, cost-effectiveness analy-
ses should directly compare all relevant treatment 
alternatives based on all available data. “Head-to-head”
clinical trials directly comparing all treatment alternatives
are seldom available, requiring the use of indirect trial evi-
dence to make the required comparisons. We illustrate the
use of formal methods to make such comparisons using
two recent cost-effectiveness analyses commissioned for
the National Institute for Clinical Excellence (NICE).
METHODS: The clinical trial evidence available to
inform the evaluations consisted of a mixed set of com-
parisons, such as drugs A vs. B , B vs. C, A vs. D. The
model parameters required to perform the required direct
comparison of the drugs (A vs. B. vs. C.) were estimated
jointly from the available data using a generalized linear
model in a Bayesian hierarchical framework. This was
implemented using Markov Chain Monte Carlo tech-
niques. RESULTS: Direct comparisons of 9 anti-epilepsy
drugs and 5 drugs for the acute-manic episode in bipolar
disorder were undertaken based on data from 27 and 7
trials, respectively. In epilepsy, the analysis showed that,
above a cost-effectiveness threshold of £20,000 per
QALY, the newer adjunct therapies were likely to be cost-
effective, although there was considerable uncertainty in
these results. In bipolar disorder, olanzapine was cost-
effective above a threshold of £7000 per responder. The
use of this analytical approach avoided the need to restrict
the analysis solely to the pairwise treatment comparisons
made in existing trials. Cost-effectiveness acceptability
curves were derived which incorporate the additional
uncertainty associated with the observed heterogeneity
between trials. CONCLUSIONS: The use of formal
analysis of mixed treatment comparisons is likely to play
an important role in reimbursement decisions. Further
research is needed into how additional uncertainty asso-
ciated with unobserved heterogeneity can be incorporated
into cost-effectiveness models.
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OBJECTIVE: To estimate actual use of beneﬁt/risk and
beneﬁt/cost outcomes in health systems decision making.
METHODS: Respondents were selected from public and
private payers, provider organizations, technology ﬁrms,
regulatory agencies and universities in France, Sweden,
UK and US. A survey questionnaire was developed and
pre-tested with 15 people. After modiﬁcation, the survey
was administered to 116 selected people. We asked about
actual use, and examples, by them and their organization
of results from beneﬁt/risk and beneﬁt/cost evaluations in
making decisions on acceptance or rejection of new, and
delisting current, health care technologies. RESULTS: A
total of 104 (89.7%) respondents completed the survey.
Every organization clearly used beneﬁt/risk results in
making decisions about accepting, using, rejecting and
deleting technologies. Surprisingly, nearly every organi-
zation also used economic outcomes to help make deci-
sions. Such results may not have always been formal
beneﬁt/cost evaluations (i.e., about 50% used budget
impact primarily) but there was at the least the recogni-
tion about making trade-offs of beneﬁts and costs among
alternatives. CONCLUSIONS: These results are contrary
to other published studies, based mainly on opinions and
perceptions that found little use of economic analysis in
health care decision making. Post hoc studies of actual
decisions made in UK, Australia of formal analyses, and
in Canada of less formal methods, conﬁrmed use of
beneﬁt/cost results. Measuring actual behavior on use of
economic outcome evaluations in health care decision
making provides different answers than soliciting 
opinions and perceptions of others’ use of these results.
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OBJECTIVE: The purpose of this study is to evaluate 
the effect of an evidence-based asthma disease manage-
ment program in patients’ health-related quality of life
(HRQL). METHODS: A total of 54 asthmatic adult
patients participated in the before and-after study in one
of the managed care organisations in Hungary. The
program included the development and use of evidence-
based protocols, patient education, asthma nurse consul-
tation and self-management programs. On entering the
study, after 6 months and after 12 months patients’
HRQL was measured using the generic utility question-
naire, the EQ-5D and the speciﬁc Asthma Quality of Life
Questionnaire (AQLQ). Statistical signiﬁcance was tested
with paired samples T-test. RESULTS: A total of 24
patients completed the questionnaires on all 3 occasions.
The mean baseline score was 0.79, 69.95, and 4.16 for
the EQ-5D index, EQ-5D VAS, and the AQLQ overall,
respectively. Baseline scores of patients with and without
complete follow-up data did not differ from each other.
At 6 months there was a signiﬁcant mean increase of 
0.11 (p = 0.007) and 10.0 (p = 0.004) in the index and
the VAS scores, respectively. After 12 months, the index
score was maintained at 0.89, with a mean increase of
0.10 from baseline (p = 0.013). The VAS score continued
to grow to 84.48 reﬂecting an overall increase of 14.53
(p < 0.001). At 12 months, signiﬁcantly less patients
reported problems in mobility and anxiety/depression.
Both the domain levels and overall AQLQ scores
improved at 6 months (p < 0.001). At 12 months, this
change remained signiﬁcant. Improvements in Symptom
and Emotion domains were large, 0.84 (p < 0.001) and
0.82 (p < 0.001) respectively. CONCLUSIONS: Evi-
dence-based asthma disease management programs can
signiﬁcantly improve patients’ HRQL already after 6
months, and this improvement can be maintained after
12 months. Importantly, the magnitude of achievable
improvement in HRQL corresponded to a difference pre-
viously observed between two asthma disease control
level groups.
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OBJECTIVES: Aortic valve replacement surgery has
become increasingly common. One of the primary issues
in choice of valve is patient quality of life. We obtained
SF-36 scores on patients following aortic valve replace-
ment surgery to determine how they compared with 
community norms and across valve types. METHODS:
Operative data were obtained from an adult cardiac
surgery database maintained by the department and con-
forming to STS data element deﬁnitions where applica-
ble. All patients receiving aortic valve replacement
between January 1992 and July 1997 were sent quality
of life surveys in the mail. SF-36 scores were calculated
using algorithms provided by QualityMetric Incorporated
and compared to general US population means and
between valve types (mechanical, bioprosthetic, or stent-
less bioprosthetic). RESULTS: Of 743 eligible patients,
329 returned the QOL surveys (43%). There were no dif-
ferences in age, gender or surgery type between patients
who did and did not return their surveys. Means on all
SF-36 subscales were comparable between valve patients
and Age 65–74 population norms. The greatest decre-
ment was seen in the general health item. Population
mean versus valve patient mean were as follows: PF 44.5
vs. 44.1; RP 45.5 vs. 44.1; BP 47.8 vs. 50.8; GH 48.4 vs.
46.0; VT 51.6 vs. 50.1; SF 50.1 vs. 50.2; RE 48.63 vs.
46.5; MH 52.7 vs. 52.1. Valve type had no effect on SF-
36 subscales. CONCLUSIONS: Aortic valve replacement
surgery provides patients with general quality of life
equivalent to that of the US population in the same age
group. All types of valves appear to have equivalent
effects on quality of life. Further study with more spe-
cialized measurement instruments are necessary to deter-
mine whether there are more disease speciﬁc differences
in quality of life following aortic valve replacement
surgery.
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OBJECTIVE: The purpose of this study was to examine
the economic and quality of life (QoL) impact of seasonal
allergic conjunctivitis in Oxfordshire. METHODS: Par-
ticipants were recruited from either general practices, or
the casualty department of the Oxford Eye Hospital
(OEH). The inclusion criteria for cases were that partic-
ipants: 1) experienced itchy, bloodshot and watering eyes
at some time between February and August every year
since 1999, and 2) considered it likely that this was in
response to seasonal allergens. Participants completed the
EQ-5D Health Questionnaire, the Rhinoconjunctivitis
Quality of Life Questionnaire, the National Eye Institute
(US) Visual Functioning Questionnaire 25, and a specially
developed Health Economic and Demographic Question-
naire. RESULTS: Most participants in both groups were
female (67.5% in SAC and 70% in control group, P =
0.565). Weekly earnings were lower in the SAC group 
(P < 0.001), as the SAC group also worked fewer hours
per week (P < 0.001). Participants with SAC also experi-
